克罗恩病患者早期启动肿瘤坏死因子拮抗剂治疗相比晚期启动可降低费用
该研究构建加拿大克罗恩病(CD)患者的马尔可夫模型,比较确诊2年内(早期)与超过2年(晚期)启动英夫利西单抗或阿达木单抗治疗的终生成本效果。早期启动英夫利西单抗较晚期多获得0.72质量调整生命年(QALY)并节省50,418美元;早期启动阿达木单抗多获得0.54 QALY并节省43,969美元。在50,000美元支付意愿阈值下,早期启动两种药物具有成本效果的概率均为74%。
要点
- 早期启动英夫利西单抗较晚期多获得0.72 QALY并节省50,418美元。
- 早期启动阿达木单抗较晚期多获得0.54 QALY并节省43,969美元。
- 在50,000美元支付意愿阈值下,早期启动两种药物具有成本效果的概率均为74%。
核心结论
- 在马尔可夫模型分析中,确诊CD后2年内启动英夫利西单抗或阿达木单抗治疗,相比超过2年后启动,可显著节省费用并增加QALY。
研究设计与样本
- 构建加拿大CD假设队列的马尔可夫模型,模拟启动英夫利西单抗或阿达木单抗治疗后的疾病进展。
- 使用已发表的失应答率比较早期(确诊2年内)与晚期(超过2年)启动抗TNF治疗的终生成本效果。
- 转移概率和效用值通过文献检索获得,费用来自阿尔伯塔省卫生部,并采用敏感性分析刻画不确定性。
主要发现
- 早期启动英夫利西单抗较晚期多获得0.72 QALY并节省50,418美元。
- 早期启动阿达木单抗较晚期多获得0.54 QALY并节省43,969美元。
- 在50,000美元支付意愿阈值下,早期启动英夫利西单抗或阿达木单抗治疗具有成本效果的概率均为74%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antagonists of tumor necrosis factor (TNF) are effective for induction and maintenance of remission of Crohn's disease (CD) and are generally prescribed when patients do not respond to conventional, less-costly medical therapies. Early initiation of anti-TNF therapy reduced rates of surgery and dose escalation due to loss of response. However, these drugs are expensive, so studies are needed on the cost effectiveness of early initiation. We aimed to determine the cost effectiveness of initiating treatment early in the disease course (within 2 years of CD diagnosis) vs later in the disease course (more than 2 years after diagnosis). METHODS: We constructed a Markov model of a hypothetical cohort of patients with CD in Canada to simulate disease progression after initiation of infliximab or adalimumab therapy. We used published loss-of-response rates to compare the lifetime cost effectiveness of early vs late initiation of anti-TNF therapies. Transition probabilities and utilities were obtained through a literature search, and costs were obtained from the Alberta Ministry of Health. Sensitivity analysis was used to characterize uncertainty. RESULTS: Early initiation of infliximab yielded an additional 0.72 quality-adjusted life-years (QALYs) and saved $50,418 compared with late initiation. Early initiation of adalimumab yielded an additional 0.54 QALYs and saved $43,969. At a willingness-to-pay threshold of $50,000, early initiations of infliximab or adalimumab therapy had a 74% chance of being cost effective compared with late initiation. CONCLUSIONS: In a Markov model analysis, we found initiation of either infliximab or adalimumab within 2 years of CD diagnosis to provide significant cost savings and QALYs compared with later initiation (more than 2 years after diagnosis).
引用
- Beilman CL, Kirwin E, Ma C, et al. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. Clin Gastroenterol Hepatol. 2018. PMID: 30056180. doi:10.1016/j.cgh.2018.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。